Sartorius Stedim Biotech S.A. (FRA:56S1)
Germany · Delayed Price · Currency is EUR | Market Cap | 15.36B -2.9% |
| Revenue (ttm) | 2.98B +4.4% |
| Net Income | 268.10M +31.2% |
| EPS | 2.76 +30.7% |
| Shares Out | n/a |
| PE Ratio | 57.30 |
| Forward PE | 32.01 |
| Dividend | 0.69 (0.38%) |
| Ex-Dividend Date | Mar 31, 2026 |
| Volume | n/a |
| Average Volume | 10 |
| Open | 180.20 |
| Previous Close | 188.40 |
| Day's Range | 180.20 - 180.20 |
| 52-Week Range | 159.90 - 223.40 |
| Beta | n/a |
| RSI | 54.45 |
| Earnings Date | Apr 23, 2026 |
About Sartorius Stedim Biotech
Sartorius Stedim Biotech S.A. engages in the production and sale of instruments and consumables for the biopharmaceutical industry worldwide. The company offers various products, such as cell lines; cell culture media; bioreactors; reagents; advanced therapies; and a range of products for separation, purification, and concentration processes, as well as products and systems for storage and transportation of intermediate and finished biological products. It also provides fluid management services; biolayer interferometry instruments; microbiolog... [Read more]
Financial Performance
In 2025, Sartorius Stedim Biotech's revenue was 2.97 billion, an increase of 6.74% compared to the previous year's 2.78 billion. Earnings were 265.60 million, an increase of 51.68%.
Financial StatementsNews
Sartorius Stedim Biotech Q1 Profit Rises On Revenue Growth; Confirms FY26 Outlook
(RTTNews) - Sartorius Stedim Biotech SA (SDMHF) reported Thursday higher profit and revenues in its first quarter. Further, the firm maintained its fiscal 2026 outlook.
Sartorius Stedim Biotech and Nanotein Technologies Partner to Advance Cell Therapy Manufacturing
AUBAGNE, France--(BUSINESS WIRE)-- #CGT--Sartorius Stedim Biotech and Nanotein Technologies Partner to Advance Cell Therapy Manufacturing.
Bio Usawa Biotechnology and Sartorius Stedim Biotech Forge Partnership to Pioneer Biopharmaceutical Manufacturing in Africa
KIGALI, Rwanda and SAN FRANCISCO and AUBAGNE, France, July 29, 2025 (GLOBE NEWSWIRE) -- Bio Usawa Biotechnology, Ltd. (Bio Usawa), a leading African biotechnology firm, and Sartorius Stedim Biotech, a...
Sartorius Stedim Biotech and Sensible Biotechnologies Partner to Scale Up Sensible's Unique Cell-Based mRNA Design and Manufacturing Platform
AUBAGNE, France & BRATISLAVA, Slovakia--(BUSINESS WIRE)--Sartorius Stedim Biotech and Sensible Biotechnologies are scaling up a unique cell-based manufacturing platform for clinical-grade therapeutic ...
Sartorius, Sartorius Stedim Biotech shares jump after results beat
Shares in Sartorius jumped 15.6% on Tuesday after the Franco-German lab supplies maker's preliminary annual results beat expectations and despite a cautious outlook for 2025.
10 stocks for investors looking for ‘wonderful companies at a fair price'
As money managers talk about various methods of selecting quality companies, investors might also think about diversification, which can lower risk and broaden opportunities.
Sartorius, Sartorius Stedim shares fall after Polyplus acquisition
Shares in German pharmaceutical and laboratory equipment supplier Sartorius AG and its France-listed subsidiary Sartorius Stedim Biotech SA DIM, -6.51% fell in opening trade on Friday after the compan...